Covid19 Clinical Trial
Official title:
Adjuvant Therapeutic Effects of Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19
COVID-19 is impacting on health systems in Brazil and worldwide. Reducing the risk of clinical deterioration and prolonged disease duration in hospitalized patients with COVID-19 may alleviate the burden caused by the pandemic. Melatonin (N-acetyl-5-methoxytryptamine) has demonstrated antiapoptotic, antioxidative, and anti-inflammatory roles and has been suggested as a potential protector against organ injuries and even mediate lower mortality rates after polymicrobial sepsis in animal models. Melatonin agonists may modulate protective effects against acute lung injury and play a clinical role in individuals with SARS-CoV-2 infection. The investigators proposed a clinical trial testing the effects of ramelteon 8mg in hospitalized patients with COVID-19.
The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) pandemic, also denominated
Coronavirus Disease 2019 (COVID-19), is currently challenging health systems in Brazil and
worldwide. The mortality rate of confirmed cases of COVID-19 in Brazil seems to be close to
twice that of countries like Germany and Canada. (1-3) The resulted viral interstitial
pneumonia can lead to severe hypoxemic respiratory failure, overcrowded intensive care units
(ICUs), shortages of equipment and personnel, and increased mortality. (4-6)
Some reasons for higher mortality risk in Brazil can be related to an increased propensity of
clinical worsening in hospitalized patients. Consequently, reducing the risk of clinical
deterioration and prolonged disease duration in hospitalized patients with mild-to-moderate
COVID-19 has become a priority to reduce the burden of such pandemic and the admission to
ICUs. However, to our knowledge, few and complex specific interventions have been tested
targeting outcomes related to a reduction of the immediate risk of severe disease and
prolonged hospitalization in inpatients with mild-to-moderate clinical signs and symptoms.
Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized mainly by the pineal gland
and also by other nonendocrine organs, including the immune system. Among its multiple
properties, melatonin has demonstrated antiapoptotic, antioxidative, and anti-inflammatory
roles exerted via both receptor-dependent and receptor-independent signalling cascades. (7,8)
It has been suggested that melatonin receptors activation protects against organ injuries.
(9-10). Additionally, melatonin receptors can mediate lower mortality rates after
polymicrobial sepsis in animal models. (11)
Melatonin potentially modulates immune response by enhancing the secretion of
anti-inflammatory cytokines including IL-10, which is involved in the Th2-like immune
response. (12) IL-10 has effects on a myriad of cell types and, in lung cells under damaging
circumstances, its production turns undermined. (13) Recent findings indicated that melatonin
receptors are modulators of protective effects against acute lung injury induced by the
ventilator in rats through the up-regulation of IL-10 production. (14) This evidence upsurged
testing the effects of ramelteon, a potent and highly selective agonist of high-affinity
melatonin receptors 1 (MT1) and MT2, which further displays antioxidative and
anti-inflammatory properties. (15-17) Melatonin agonism may play a clinical role in
individuals with acute lung injuries, including those induced by SARS-CoV-2 infection, which
has not yet been investigated. The investigators designed a clinical trial testing standard
care versus ramelteon 8mg under diverse clinical and laboratory outcomes related to the
COVID-19 in hospitalized patients with this condition.
References
1. Robert Koch Institut. Coronavirus Disease 2019 (COVID-19) Daily Situation Report of the
Robert Koch Institute. Available from:
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Gesamt.h
tml Updated 14.05.20
2. DATASUS. Ministério da Saúde do Brasil. Available from: https://covid.saude.gov.br/.
Atualizada em: 14/05/2020
3. Government of Canada. Coronavirus Disease 2019 (COVID-19): Daily Epidemiology Update.
Available from:
https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infectio
n.html?topic=tilelink#a1. Updated 14.05.20.
4. P.H.S. Pelicioni, S.R. Lord. COVID-19 will severely impact older people's lives, and in
many more ways than you think!. Braz J Phys Ther, (2020),
http://dx.doi.org/10.1016/j.bjpt.2020.04.005
5. [3] R.D. Branson, D.R. Hess, L. Rubinson. SARS CoV-2: Guidance Document. American
Association for Respiratory Care, (2020),
6. World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation Report 46.
(2020)
7. Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos
DP. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016;173:2702-2725.
doi: 10.1111/bph.13536.
8. Radogna F, Paternoster L, Albertini MC, Cerella C, Accorsi A, Bucchini A, Spadoni G,
Diamantini G, Tarzia G, De Nicola M, et al. Melatonin antagonizes apoptosis via receptor
interaction in U937 monocytic cells. J Pineal Res. 2007;43:154-162. doi:
10.1111/j.1600-079X.2007.00455.x.
9. Lochner A, Genade S, Davids A, Ytrehus K, Moolman JA. Short- and long-term effects of
melatonin on myocardial post-ischemic recovery. J Pineal Res. 2006;40:56-63. doi:
10.1111/j.1600-079X.2005.00280.x.
10. Rezzani R, Rodella LF, Bonomini F, Tengattini S, Bianchi R, Reiter RJ. Beneficial
effects of melatonin in protecting against cyclosporine A-induced cardiotoxicity are
receptor-mediated. J Pineal Res. 2006;41:288-295. doi: 10.1111/j.1600-079X.2006.00368.x.
11. Fink T, Glas M, Wolf A, Kleber A, Reus E, Wolff M, Kiefer D, Wolf B, Rensing H, Volk T,
Mathes AM. Melatonin receptors mediate improvements of survival in a model of
polymicrobial sepsis. Crit Care Med. 2014;42:e22-e31. doi: 10.1097/CCM.0b013e3182a63e2b.
12. Ren Wenkai, Liu Gang, Chen Shuai, Yin Jie, Wang Jing, Tan Bie, Wu Guoyao, Bazer Fuller
W., Peng Yuanyi, Li Tiejun, Reiter Russel J., Yin Yulong. Melatonin signalling in T
cells: Functions and applications. Journal of Pineal Research. 2017;62(3):e12394. doi:
10.1111/jpi.12394.
13. Hokenson MA, Wang Y, Hawwa RL, Huang Z, Sharma S, Sanchez-Esteban J. Reduced IL-10
production in fetal type II epithelial cells exposed to mechanical stretch is mediated
via activation of IL-6-SOCS3 signalling pathway. PLoS One. 2013;8:e59598. doi:
10.1371/journal.pone.0059598.
14. Wu GC, Peng CK, Liao WI, Pao HP, Huang KL, Chu SJ. Melatonin receptor agonist protects
against acute lung injury induced by ventilator through up-regulation of IL-10
production. Respir Res. 2020 Mar 6;21(1):65. doi: 10.1186/s12931-020-1325-2.
15. Mathes AM, Kubulus D, Waibel L, Weiler J, Heymann P, Wolf B, Rensing H. Selective
activation of melatonin receptors with ramelteon improves liver function and hepatic
perfusion after hemorrhagic shock in the rat. Crit Care Med. 2008;36:2863-2870. doi:
10.1097/CCM.0b013e318187b863.
16. Shimizu N, Nozawa M, Sugimoto K, Yamamoto Y, Minami T, Hayashi T, Yoshimura K, Ishii T,
Uemura H. Therapeutic efficacy and anti-inflammatory effect of ramelteon in patients
with insomnia associated with lower urinary tract symptoms. Res Rep Urol.
2013;5:113-119.
17. Zhou W, Zhang X, Zhu CL, He ZY, Liang JP, Song ZC. Melatonin receptor agonists as the
"Perioceutics" agents for the periodontal disease through modulation of Porphyromonas
gingivalis virulence and inflammatory response. PLoS One. 2016;11:e0166442. doi:
10.1371/journal.pone.0166442
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |